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Telomerase is an enzyme which adds repeated telomere sequences
(TTAGGG) to chromosome ends and has an RNA component
complementary to the telomeric repeat sequence (Moyzis et al,
1988; Zakian, 1989). Its catalytic protein component synthesizes
telomeric DNA directly onto the ends of chromosomes by the
process of reverse transcription of the RNA template (Greider and
Blackburn, 1989; Bhattacharyya and Blackburn, 1994; Feng et al,
1995; Kirk et al, 1997). Telomerase activity has been detected in
immortalized and tumour cells in vitro and in primary tumour
tissues, most fetal tissues, and normal adult male reproductive
cells and represents an important difference between normal
somatic cells and cancer cells (Kim et al, 1994; Hiyama et al,
1995; Rhyu, 1995; Wright et al, 1996; Shay and Bacchetti, 1997;
Sedivy, 1998). Telomerase activity in lysates extracted from
tumour cells and tumour tissues is not inhibited by mixture with
cell lysates from normal cells, leading to the hypothesis that
normal cells contain and express genes which repress the telom-
erase activity of tumour cells. One approach to map putative
telomerase repressor genes to specific chromosomes is the identi-
fication of deletions in genome of telomerase-positive cells and
tissues. We have previously reported that a senescence-inducing
gene on normal human chromosome 3p represses telomerase
activity in human renal cell carcinoma cells through down-
regulation of the catalytic subunit gene of human telomerase
(hEST2/hTERT) (Koi et al, 1989; Shimizu et al, 1990; Ohmura 
et al, 1995) and, furthermore, the location of the telomerase-
repressor gene has been narrowed to the 6 regions in 3p12–3p24.3
(Yashima et al, 1997; Mehle et al, 1998; Tanaka et al, 1998; Vieten
et al, 1998; Cuthbert et al, 1999). Of interest, Steenbergen et al
revealed that the loss of heterozygosity (LOH) at either chromo-
some 3p or 10p loci correlated with the onset of telomerase activa-
tion during immortalization of human keratinocytes, raising the
possibility that a gene on chromosome 10p also may function as a
telomerase repressor. Moreover, loss of heterozygosity (LOH)
on 10p has been observed in multiple human cancers such as
gliomas, oesophageal carcinomas, and melanomas (Robertson 
et al, 1999), prompting us to focus on this chromosomal arm. We
recently presented evidence that a repressor for hTERT was
located on 10p15.1 (between markers WI-4752 and D10S1728)
(Nishimoto et al, 2001). 
We chose hTR expression as a marker of telomerase expres-
sion because hTERT shows relatively weak and unstable signals
by in situ hybridization. To investigate the relationship between
hTR expression and LOH we had to identify tumours which were
heterogeneous for telomerase activity. While most tumours are
strongly positive for hTR expression, we identified heterogenous
hTR repressor-related gene on human chromosome
10p15.1 
N Miura1, N Onuki2, A Rathi1, A Virmani1, S Nakamoto3, Y Kishimoto4, Y Murawaki5, H Kawasaki5, J Hasegawa4, 
M Oshimura6, WD Travis7 and AF Gazdar1
1Hamon Center for Therapeutic Oncology Research, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8593,
USA; 2Department of Surgery, Tokyo Women’s Medical College, Tokyo 162-8666, Japan; 3Department of Laboratory Medicine, Tottori Prefectural Central
Hospital, Tottori, Tottori 680-0901, Japan; 4Department of Clinical Pharmacology, Tottori University, Yonago, Tottori 683-8503, Japan; 5The Second Department
of Internal Medicine, Tottori University, Yonago, Tottori 683-8503, Japan; 6Department of Molecular and Cell Genetics, School of Life of Sciences, Faculty of
Medicine, Tottori University, Yonago, Tottori 683-8503, Japan; 7Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology,
Washington, DC 20306-6000, USA 
Summary Somatic cells express genes that suppress telomerase activity and these genes may be inactivated in tumour cells. We postulated
that cancer cells acquire immortality by activation of telomerase by the loss of such a gene. We have reported recently that a telomerase
repressor gene may be located on 10p15.1 by deletion mapping using microcell-mediated chromosome transfer (MMCT), radiated microcell
fusion (RMF), fluorescent in situ hybridization (FISH) and STS analysis. To independently confirm this result, we correlated expression of RNA
component of telomerase (hTR) as a marker of telomerase expression by in situ hybridization with allelic loss in pulmonary carcinoid tumours.
Unlike most malignant tumours, pulmonary carcinoids (which are low-grade malignant tumours) are heterogeneous for telomerase
expression. Loss of 5 closely spaced polymorphic markers on 10p15.1, especially D10S1728, were highly correlated with hTR expression. In
an additional experiment, 10p15.1 showed higher and more significant correlation than any region of 3p where it has been predicted as
another chromosomal location of telomerase repressor with allelic loss of the region. Our findings strongly suggest that 10p15.1 harbours a
gene involved in repression of telomerase RNA component in human somatic cells and each putative repressor (on 3p and 10p) may act
independently. © 2001 Cancer Research Campaign http://www.bjcancer.com 
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expression in pulmonary carcinoids which are low-grade
neuroendocrine tumours. 
MATERIALS AND METHODS 
A mapping by LOH analysis using STS markers 
Tumour specimens 
A total of 59 neuroendocrine lung tumours were collected from the
files of the members of the Pathology Panel of the International
Association for the Study of Lung Cancer (IASLC). Histological
slides were reviewed by WT, a pathologist familiar with the 
classification of neuroendocrine lung tumours, and the cases were
categorized according to standardized histopathological criteria
described previously. The case material consisted of 10 TCs, 11
ACs as low-malignant lung tumours (Onuki et al, 1999). 
Microdissection and DNA extraction 
Serial 5 mm sections were cut from archival, formalin-
fixed, paraffin-embedded tissue. All slides were stained with
haematoxylin-eosin, and one of the slides was cover slipped. The
cover-slipped slide was used as a guide to localize regions of
interest for microdissection in the non-cover-slipped slides.
Microdissection and DNA extraction were performed as previ-
ously described from sections of each sample. Cells from lymph
nodes without metastasis or histologically normal lung were used
as a source of constitutional DNA from each case. After DNA
extraction, 5 µ l of the proteinase K digested samples, containing
DNA from at least 100 cells, were used for each PCR-based
analysis. 
Polymorphic DNA markers and PCR-LOH analysis 
To evaluate LOH and MA in neuroendocrine tumour as low-
malignant lesions of SCLC, we used primers flanking 16 di-, 
tetra-and multinucleotide microsatellite repeat polymorphisms
located at the chromosomal locations 10p15 and all the data were
compared with those from 3p14.1–21.3. The microsatellite
markers and the chromosomal regions analysed were as follows:
10p15 (D10S249, D10S594, D10S602, D10S591, D10S1713,
D10S189, D10S1751, D10S1691, AFM154YB4, CHCL.84C03,
WI-5574, D10S1779, D10S226, D10S1728, D10S1649,
D10S1712, D10S1720, CHCL.117B02, WI-600, D10S547) and
3p14.1–21.3 (D3S1029, D3S1478, KI.CA, D3S1573, ITIH-1,
D3S1447, D3S1766). The primer sequences used for LOH studies
were obtained from the Genome Database. For all samples, multi-
plex PCR (up to 8 primers) was performed in the first amplifica-
tion, followed by uniplex PCR for individual microsatellite
markers as previously described. LOH was recognized by visual
detection of complete absence of upper or lower allele. MAs were
identified by a shift in size of one or both parental alleles
compared to constitutional DNA (from normal cells) from the
same individual. In the multiplex PCR, 8 markers were amplified
in the same reaction using extracted DNA from at least 100
microdissected nuclei. Volumes of 50 µ l were used for each multi-
plex reaction, containing 20 mM TRIS (pH 8.3), 50 mM KCl, 2.5
mM MgCl2, 400 mM of each deoxynucleoside triphosphate
(dATP, dCTP, dGTP, dTTP), 0.5 µ M of each forward and 
reverse primer, and 3.5 units of AmpliTaq Gold (Perkin Elmer,
Branchburg, NJ). The first PCR product was then diluted 1:10 in
double distilled sterile water. The second PCR reaction was
performed in 10 µ l reaction volume containing 20 mM Tris (pH
8.3), 50 mM KCl, 1.5 mM MgCl2, 100 mM of each deoxynucleo-
side triphosphate, 0.5 µ M of forward and reverse primer, 0.25 unit
of AmpliTaq polymerase (Gibco-BRL, Alameda, CA), 0.25 µ l of
(α -32P) dCTP (3000 Ci mol–1, 10 mCi ml–1), (Amersham Life
Sciences, Arlington Heights, IL), and 2 µ l of diluted first PCR
product. In both PCR reactions, a ‘touch-down’ PCR method was
performed. Briefly, after initial denaturation at 94˚C for 4 to 8 min,
11 cycles each consisting of denaturation at 95˚C for 20 s,
annealing at 65–56˚C for 55 s and extension at 72˚C for 20 s were
performed, followed by an additional 24 cycles which included
denaturation at 90˚C for 20 s, annealing at 55˚C for 
20 s and extension at 72˚C for 20 s. Then, a 5 µ l aliquot of each
second PCR reaction was diluted 1:4 with loading buffer, heat
denatured, and separated by electrophoresis on a denaturing 6%
polyacrylamide gel containing 7 M urea. A water blank control
was included in all gels. LOH was scored in informative cases by
visual detection of complete absence of the one allele. 
hTR expression in situ hybridization (ISH) 
To compare the result of LOH analysis using STS markers with
hTR expression, we performed cRNA in situ hybridization in the
low-malignant grade of lung tumour (TCs and ACs). 
Preparation and prehybridization of tissue sections for ISH 
Paraffin-embedded (5 mm) tissue sections of 6 tumour-negative
and 4 tumour-positive lymph nodes were cut onto Superfrost/Plus
slides (Fisher Scientific, Pittsburgh, PA, USA). The sections were
deparaffinized, rehydrated in phosphate-buffered saline (PBS),
and treated with proteinase K (20 mg ml–1) in 50 mM Tris-HCL
(pH 7.5), 5 mM EDTA for 20 min at room temperature. After
rinsing for 5 min in PBS, sections were postfixed in 4%
paraformaldehyde/PBS, rinsed in water, and acetylated in freshly
prepared 0.25% acetic anhydride/0.1 M triethanolamine for 10
min. The slides were dehydrated in gradually increasing concen-
trations of ethanol prior to hybridization. 
Probe preparation for ISH 
The plasmid pGEM-5Zf(+) (Promega Corp., Madison, WI, USA)
containing a human telomerase RNA (hTR) complementary DNA
(560 nucleotides), obtained from Geron Corp, Menlo Park, CA,
USA, was used as a template to generate sense and antisense
probe. [35S]UTP-labelled single-stranded RNA probes were
synthesized according to manufacturer’s (Ambion, Inc, Austin,
TX, USA) conditions. Transcripts were alkali hydrolysed to
generate probes with an average length of 200 nucleotides for effi-
cient hybridization, purified using G-50 column (Boehringer
Mannheim Corp, Indianapolis, IN, USA), and precipitated in
ethanol. The probes were resuspended in 30 µ l of 100 mM dithio-
thritol. The specific activity of the radiolabelled probes, aliquoted
and stored at –80˚C until use, was approximately 3 × 107 cpm mg–1
template DNA. 
Hybridization and washing procedures 
Sections were hybridized overnight at 52˚C in 50% deionized
formamide, 0.3 M NaCl, 20 mM TRIS-HCl (pH 7.5), 5 mM
EDTA, 10 mM NaH2PO4 (pH 8.0), 10% dextran sulfate, 1 ×
Denhardt’s, 500 mg ml–1 total yeast RNA, 10 mM dithiothritol, and
50000 cpm ml–13 5 S-labelled cRNA probe. The tissue was subjected
to stringent washing at 50˚C in 5 × SSC, 10 mM dithiothritol for 30
min, at 65˚C in 50% formamide, 2 × SSC, 10 mM DTT for 20 min1512 N Miura et al 
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and washed twice at 37˚C in 0.4 M NaCl, 10 mM Tris-HCl (pH
7.5), 5 mM EDTA for 10 min before treatment with 20 mg ml–1
RNase A at 37˚C for 30 min. Following washes in 2 × SSC and 0.1
× SSC for 10 min at 37˚C, the slides were dehydrated and dipped in
Kodak NTB-2 nuclear track emulsion and exposed for 3 wk in light
tight boxes with dessicant at 4˚C. The microautradiographs were
developed in Kodak Dektol developer (3.5 min), washed in water
(20 s), fixed in Kodak fixer (7 min), rinsed in water, counterstained
in haematoxylin and eosin. ISH for hTR was performed as
described previously (Yashima et al, 1997). To confirm the pres-
ence of intact RNA, replicate slides from each sample utilized for
hTR expression were also tested for expression of a housekeeping
gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The
Xba/HindIII fragment from the GAPDH cDNA in pBR322
obtained from the American Type Culture Collection, Rockville,
MD, was subcloned into pBluescript. Intense GAPDH hybridiza-
tion signals were present in all sections studied. 
hTR expression was scored as follows: weak – faint expression,
detected by brightfield examination at high magnification, but
which was detected at low magnification by darkfield examination;
moderate – expression readily recognized by brightfield examina-
tion at low magnification; high – expression at a level considerably
greater than those present in normal. We estimated each level of
hTR expression as positive because even weakly positive signals
are visually distinguishable, compared with negative ones in ISH. 
RESULTS 
Comparison of hTR expression with LOH analyses 
To confirm that the region of interest was between markers
D10S226 and D10S547 on 10p15.1, and to narrow this region, we
performed LOH analysis by PCR in pulmonary low-malignant
tumours including low-grade typical carcinoid (TC) and the more
malignant atypical carcinoids (AC) (Travis et al, 1998). Because
there were no significant differences between TC and AC, we
combined the data. LOH with one or more markers was present in
53% (9/17) of telomerase positive in our samples. Also we
compared the data from 10p15 with those from 3p14.2–21.3
because we and others have reported a possibility that a telomerase
repressor may be harboured at 3p as well. Represented in Figure 1,
in 21 samples of TCs and ACs, 6 LOHs, 2 microsatellite alter-
ations (MAs), 4 not informative cases, and 10 cases without LOH
were observed with marker D10S1728, and 2 LOHs were
observed with other sequence tagged site (STS) markers on 10p15.
All the LOHs and 1 MA concorded with the expression of hTR
ISH. hTR expression and LOH in 10p15.1 showed a high concor-
dance (13 out of 15 samples: 87%). On the other hand, 9 out of 17
(53%) in 3p21.2–21.3 and 6 out of 10 (60%) in 3p14.2–21.2
showed a little lower concordance with hTR expression than that
of 10p15.1 (Figure 2). Furthermore, comparison between LOH
and hTR expression with only a marker D10S1728 revealed 81%
of concordance in lung neuroendocrine (NE) tumours. In small-
cell lung carcinomas (SCLCs), 15 out of 18 (83.3%) in 10p15.1
(D10S226, D10S1728, D10S1649, D10S1712, and D10S1720) as
markers which are located within zero genetic distance) showed
LOH and 3 out of 18 showed MAs. In large cell neuroendocrine
carcinomas (LCNECs), 14 out of 15 (93.3%) with the same
markers of 10p15 showed LOH and 1 out of 15 showed MA. Each
level (weak, moderate and high signals) of hTR expression did not
significantly correlate with the grades of carcinoid tumours.
Additionally, LOH analysis using D10S1728 which showed the
highest concordance as the hot spot was performed in 132 lung
cancer cell lines but no homozygous deletions were recognized. 
DISCUSSION 
Telomerase activity is detected in most human cancer tissues and
immortalized cells and is almost universally required for the long-
term growth of cancer cells. We and others previously reported
that the activation of telomerase is strongly associated with the
development of human hepatocellular carcinomas (HCCs) (Miura
et al, 1997). Escape from the cellular senescence programme is a
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Figure 1 Microsatellite analyses using D10S1728 in lung carcinoids. 
Two representatives in 21 cases are illustrated. In case 1, lacking hTR
expression, no allelic loss is present. In case 2, positive for hTR expression,
the lower allele is absent, indicating alleic loss (LOH). N = normal tissue, 
T = tumour 
− +
− 71
6 1 +
3p21.2− 21.3 LOH (n = 17)
− +
− 53
4 5 +
Concordance 9/17 (53%)
hTR
− +
− 70
6 3 +
D10S1728 LOH (n =16) 
Concordance 13/16 (81%)
hTR
10p15.1 LOH (n = 15)
Concordance 13/15 (87%)
hTR
3p14.2−21.2  LOH (n = 10)
− +
− 42
2 2 +
Concordance 6/10 (60%)
hTR
+
67
5 3 +
3p LOH (n = 21)
Concordance 11/21 (52%)
10p15.1 LOH
−
−
Figure 2 Correlation of 10p with 3p for hTR expression by ISH. Allelic
losses with 10p15.1 markers in carcinoid lung tumours resulted in higher
concordance with hTR expression (87%) than chromosome 3p markers. No
significant correlation between 3p and 10p was demonstrated. D10S1728
showed high concordance (81%) with hTR expression than any other
markers hRT repressor-related gene on 10p15.1 1513
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rate-limiting step during carcinogenesis (Norwood et al, 1974;
Sager, 1991; Campisi, 1997; Chiu and Harley 1997; Pereira-Smith
et al, 1998). We have recently reported the presence of another
senescence-inducing gene (Sasaki et al, 1994; Ohmura et al, 1995;
Tanaka et al, 1998) that also functions as a telomerase repressor on
human chromosome 3p (Holt et al, 1997; Meyerson et al, 1997;
Nakamura et al, 1997, 1998). In the case, telomerase repression
was due to down-regulation of the gene encoding the catalytic
subunit of human telomerase (hEST2/hTERT) (Horikawa et al,
1998). In other cases, telomerase repression during cell differenti-
ation was associated with down-regulation of the RNA component
of telomerase (hTR) (Bickenback et al, 1998). Given that LOH at
either 3p or 10p was associated with telomerase activation
(Steenbergen et al, 1996), the 2 possible telomerase-repressor
genes on 3p and 10p may be part of the same cascade of telom-
erase regulation. Alternatively, as reported in this study, the repres-
sors may have independent, but synergistic functions to regulate
the repression pathway of telomerase. Further studies will be
needed to determine the molecular basis for telomerase repression
by the 10p gene and its functional relationship to the 3p gene.
Nonetheless, our results provide new insights into the mechanism
of telomerase regulation by demonstrating that the repression of
telomerase activity in normal human somatic cells is under multi-
factorial control, which involves at least 2 telomerase-repressor
genes (Oshimura and Barrett, 1997). 
Relatively frequent alterations and deletions of chromosome
10p have been identified in many human tumours including
glioblastoma multiforme (GBM) (Bigner et al, 1990; Steck et al,
1995; Tsuda et al, 1995; Voesten et al, 1997; Kon et al, 1998),
malignant melanoma (MM) (Isshiki et al, 1993), and meningioma
(Rempel et al, 1993). Since human glioblastoma hybrid cells
containing an entire chromosome 10 or major portions of chromo-
some 10 exhibited a suppression in their ability to grow anchorage
independently and to form tumours in nude mouse (Pershouse 
et al, 1993), the presence of suppressor gene in chromosome 
10p has been suggested. In high-grade astrocytomas such as
glioblatoma multiforme (GBM), 3 distinct regions of frequent
chromosome 10 deletion have been identified, and one of them is
the distal half of the short arm defined by markers D10S33,
D10S28, and D10S34 (Karlbom et al, 1993; Steck et al, 1995).
This indicates that several distinct tumour suppressor genes may
be present on chromosome 10 and may contribute to the progres-
sion of malignant tumours. Further investigation has also indicated
that LOH on 10p was frequently identified in GBM and MM, and
10p as well as 3p encodes genes involved in telomerase regulation
(Steenbergen et al, 1996). 10p15 was structurally altered in malig-
nant melanoma (10pter-p13) and GBM (10pter-p14) and is
included in a candidate of locus (10pter-q11) (Sanchez et al, 1996)
has pointed out that a telomerase repressor may exist. Frequent
LOH on 10p has not been reported in human HCCs. This may
suggest that the telomerase-repressor/senescence-inducing gene
on 10p is implicated in development of only a fraction of HCCs or
fewer STS markers in chromosome 10p than those in other chro-
mosomes have kept the detection of LOH away from us. Actually,
we detected 67% of LOH (4/6) at D10S1649 in HCCs (unpub-
lished). Conversely, it is plausible that the 10p15.1 gene is
involved in human cancers other than HCC, such as neuroen-
docrine lung tumour (we detected 56% of LOH (5/9) at D10S1728
and 63% of LOH (7/11) at D10S1712 in lung squamous cell carci-
noma). Of interest is whether a putative tumour suppressor gene(s)
on 10p for gliomas and oesophageal cancers is identical to the
telomerase-repressor/senescence-inducing gene described in this
study. As an additional experiment, we performed allelic analyses
in microdissected lung tumours in order to confirm whether the
hot spot from deletion mapping by MMCT, RMF, and LOH
analyses using STS markers can be still identified as a hot spot.
Interestingly, as these hot spots showed a higher concordance with
the detection of telomerase activity in lung tumours than any part
of 3p, though it is true that 3p still shows high concordance (71%)
with telomerase activity, a series of our study may indicate that the
gene lying around the region of our interest may be able to act as a
repressor of hTR and/or transcriptional repressor of hTERT
(Nakamura et al, 1997; Ulaner et al, 1998). 
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